Boasting a late-stage Botox me-too, Evolus files for $75M IPO
Seeking to break Allergan’s dominance in the wrinkle-reducing market, Evolus has filed for a $75 million IPO. As the Irvine, CA-based biotech is preparing to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.